Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on XNCR stock, giving a Buy rating on April 30.
Jonathan Chang has given his Buy rating due to a combination of factors related to Xencor’s promising developments and strategic positioning. The initial Phase I data for XmAb942, a treatment being developed for autoimmune conditions, showed encouraging results in terms of safety and efficacy, with a favorable pharmacokinetic and pharmacodynamic profile in healthy volunteers. This suggests potential for further development, as evidenced by Xencor’s plans to initiate a Phase IIb study for XmAb942 in ulcerative colitis by the second half of 2025.
Additionally, Xencor’s robust pipeline, which includes other promising candidates like the XmAb TL1A x IL23p19 bispecific expected to enter clinical trials in 2026, offers multiple opportunities for success. The company’s experienced management team and strong financial position further reinforce its capability to execute its long-term strategy effectively. These factors combined make Xencor an attractive investment opportunity, justifying the Buy rating.
According to TipRanks, Chang is an analyst with an average return of -13.8% and a 26.86% success rate. Chang covers the Healthcare sector, focusing on stocks such as Genmab, Nanobiotix, and Xencor.